Table 4.

Extent of changes in clinical data during 3 months before dialysis initiation

Extent of changes in data	CERA (n = 37)	DA (n = 26)	P value
Hb level (g/dL)	−0.03 ± 1.40	−1.05 ± 1.20	0.006
ESA dosage (μg/4 weeks)	19.05 ± 52.27	38.58 ± 66.71	0.21
ERI (μg/kg/g/dL/4 weeks)	0.020 ± 0.076	0.078 ± 0.120	0.045
TSAT (%)	−0.09 ± 17.63	−5.17 ± 10.89	0.71
Ferritin (ng/mL)	−25.52 ± 78.77	−28.16 ± 65.10	0.82
eGFR (mL/min/1.73m2)	−2.75 ± 2.76	−2.68 ± 2.99	0.71
CTR (%)	2.53 ± 4.71	3.45 ± 2.71	0.54

Values are given as mean ± standard deviation

CERA continuous erythropoietin receptor activator, CTR cardiothoracic ratio, DA darbepoetin-α, eGFR estimated glomerular filtration rate, ERI erythropoietin resistance index, ESA erythropoiesis-stimulating agent, Hb hemoglobin, TSAT transferrin saturation